Hemogenyx Pharmaceuticals PLC Director/PDMR Shareholding (6565X)
May 01 2019 - 2:01AM
UK Regulatory
TIDMHEMO
RNS Number : 6565X
Hemogenyx Pharmaceuticals PLC
01 May 2019
Hemogenyx Pharmaceuticals plc
("Hemogenyx" or the "Company")
Director/PDMR Shareholding
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments designed to transform
bone marrow transplantation for the treatment of blood diseases,
announces that it has been advised that on 30 April 2019 Andrew
Wright, the Company's Financial Controller and Company Secretary
(PDMR), purchased 840,336 ordinary shares of GBP0.01 each in the
Company ("Ordinary Shares") at a price of 2.38p per share.
Following this transaction, Mr Wright now has a total beneficial
interest in 840,336 Ordinary Shares, representing approximately
0.23 per cent of the Company's issued share capital.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them:
1. Details of PDMR/person closely associated with them
("PCA")
a) Name Andrew Wright
------------------------------ ------------------------------------------------
b) Position/status Financial Controller and Company Secretary/PDMR
(non-board)
------------------------------ ------------------------------------------------
c) Initial notification/ Initial notification
amendment
------------------------------ ------------------------------------------------
2. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
--------------------------------------------------------------------------------
a) Description of Ordinary shares of 1p of Hemogenyx
the financial Pharmaceuticals plc
instrument Identification code GB00BYX3WZ24
------------------------------ ------------------------------------------------
b) Nature of the Acquisition of ordinary shares
transaction
------------------------------ ------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBP GBP0.0238 840,336
----------
------------------------------ ------------------------------------------------
d) Aggregated information Price(s) Volume(s)
* Aggregated volume GBP GBP20,000.00 840,336
----------
* Price
------------------------------ ------------------------------------------------
e) Date of the transaction 2019-04-30
------------------------------ ------------------------------------------------
f) Place of the transaction London Stock Exchange
XLON
------------------------------ ------------------------------------------------
Enquiries:
Hemogenyx Pharmaceuticals plc www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Sir Marc Feldmann, Executive Chairman
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre, Soltan
Tagiev
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249
or lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals plc ("Hemogenyx") is a publicly traded
company (LSE: HEMO) headquartered in London, with its wholly-owned
US operating subsidiaries, Hemogenyx LLC and Immugenyx LLC, located
in New York City at its state-of-the-art research facility and a
wholly-owned Belgian operating subsidiary, Hemogenyx-Cell SPRL,
located in Liège.
Hemogenyx is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx is developing two distinct and complementary products, as
well as a platform technology that it uses as an engine for novel
product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. Hemogenyx's technology has
the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHDGGDSDXXBGCG
(END) Dow Jones Newswires
May 01, 2019 02:01 ET (06:01 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024